Accuray Inc (ARAY)
1.91
+0.14
(+7.91%)
USD |
NASDAQ |
Oct 04, 16:00
1.92
+0.01
(+0.52%)
After-Hours: 20:00
Accuray SG&A Expense (Annual): 92.68M for June 30, 2024
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
June 30, 2024 | 92.68M |
June 30, 2023 | 94.45M |
June 30, 2022 | 94.06M |
June 30, 2021 | 84.54M |
June 30, 2020 | 87.40M |
June 30, 2019 | 105.58M |
June 30, 2018 | 108.24M |
June 30, 2017 | 101.24M |
June 30, 2016 | 106.93M |
June 30, 2015 | 108.82M |
June 30, 2014 | 107.22M |
Date | Value |
---|---|
June 30, 2013 | 112.10M |
June 30, 2012 | 112.22M |
June 30, 2011 | 93.77M |
June 30, 2010 | 69.66M |
June 30, 2009 | 81.72M |
June 30, 2008 | 75.01M |
June 30, 2007 | 61.80M |
June 30, 2006 | 41.11M |
June 30, 2005 | 24.49M |
June 30, 2004 | |
June 30, 2003 | 6.71M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
84.54M
Minimum
2021
94.45M
Maximum
2023
90.63M
Average
92.68M
Median
2024
SG&A Expense (Annual) Benchmarks
Boston Scientific Corp | 5.19B |
AngioDynamics Inc | 143.98M |
Baxter International Inc | 3.896B |
Masimo Corp | 664.00M |
Perspective Therapeutics Inc | 21.06M |